237 related articles for article (PubMed ID: 32767739)
1. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Nosaka T; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Sep; 40(3):314-322. PubMed ID: 32767739
[TBL] [Abstract][Full Text] [Related]
2. Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis.
Kishi T; Nakamura H; Iwata N
Psychopharmacology (Berl); 2021 Dec; 238(12):3585-3593. PubMed ID: 34476565
[TBL] [Abstract][Full Text] [Related]
3. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Yoshimura R; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Dec; 40(4):417-422. PubMed ID: 32902200
[TBL] [Abstract][Full Text] [Related]
4. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
[TBL] [Abstract][Full Text] [Related]
5. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Arango C; Ng-Mak D; Finn E; Byrne A; Loebel A
Eur Child Adolesc Psychiatry; 2020 Sep; 29(9):1195-1205. PubMed ID: 31758359
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
Kishi T; Ikuta T; Sakuma K; Okuya M; Iwata N
J Psychiatr Res; 2021 Jun; 138():444-452. PubMed ID: 33964682
[TBL] [Abstract][Full Text] [Related]
7. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.
Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A
Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Goldman R; Loebel A; Cucchiaro J; Deng L; Findling RL
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):516-525. PubMed ID: 28475373
[TBL] [Abstract][Full Text] [Related]
10. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.
Zheng W; Cai DB; Yang XH; Li L; Zhang QE; Ng CH; Ungvari GS; Li XB; Ning YP; Xiang YT
J Psychiatr Res; 2018 Aug; 103():244-251. PubMed ID: 29906709
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo, and risperidone-controlled study of lurasidone in the treatment of schizophrenia: Results of an inconclusive 6-week trial.
Higuchi T; Iyo M; Kwon JS; Chou YH; Chen HK; Chen JY; Chen TT; Huang SY; Lee JS; Saeki Y; Tanaka H; Wang TS; Wu BJ; Katoh T; Ishigouoka J
Asia Pac Psychiatry; 2019 Sep; 11(3):e12354. PubMed ID: 30912222
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone in the treatment of schizophrenia: Results of a double-blind, placebo-controlled trial in Asian patients.
Higuchi T; Ishigooka J; Iyo M; Yeh CB; Ebenezer EG; Liang KY; Lee JS; Lee SY; Lin SK; Yoon BH; Nakamura M; Hagi K; Sato T
Asia Pac Psychiatry; 2019 Jun; 11(2):e12352. PubMed ID: 30950208
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine].
Mosolov SN; Malyutin AV; Pikalov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(12):29-37. PubMed ID: 31994511
[TBL] [Abstract][Full Text] [Related]
14. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.
Ogasa M; Kimura T; Nakamura M; Guarino J
Psychopharmacology (Berl); 2013 Feb; 225(3):519-30. PubMed ID: 22903391
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies.
Calisti F; Cattaneo A; Calabrese M; Mao Y; Tocco M; Pikalov A; Goldman R
Int Clin Psychopharmacol; 2022 Sep; 37(5):215-222. PubMed ID: 35276716
[TBL] [Abstract][Full Text] [Related]
17. A network meta-analysis of the dose-response effects of lurasidone on acute schizophrenia.
Srisurapanont M; Suttajit S; Likhitsathian S; Maneeton B; Maneeton N
Sci Rep; 2021 Mar; 11(1):5571. PubMed ID: 33692392
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies.
Loebel A; Cucchiaro J; Silva R; Mao Y; Xu J; Pikalov A; Marder SR
Eur Psychiatry; 2015 Jan; 30(1):26-31. PubMed ID: 25280429
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.
Costamagna I; Calisti F; Cattaneo A; Hsu J; Tocco M; Pikalov A; Goldman R
Eur Psychiatry; 2021 May; 64(1):e35. PubMed ID: 33966678
[TBL] [Abstract][Full Text] [Related]
20. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.
Loebel A; Silva R; Goldman R; Watabe K; Cucchiaro J; Citrome L; Kane JM
J Clin Psychiatry; 2016 Dec; 77(12):1672-1680. PubMed ID: 27454547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
